SYNAIRGEN ORD 1P news, videos and press releases
For more news please use our advanced search feature.
SYNAIRGEN ORD 1P - More news...
SYNAIRGEN ORD 1P - More news...
- Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19
- Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022
- Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients
- Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022
- Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference
- Synairgen announces global strategic partnership with Ashfield Engage
- Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference
- Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients
- Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
- Non-Executive Director Appointment
- Interim results for the six months ended 30 June 2021
- Non-Executive Director Appointment
- Interim results for the six months ended 30 June 2021
- Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
- Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
- Preliminary results for the year ended 31 December 2020
- Preliminary results for the year ended 31 December 2020
- Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
- Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
- Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
- Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
- Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
- Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
- Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
- Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
- Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
- Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
- COVID-19 Clinical Programme Update
- COVID-19 Clinical Programme Update
- Synairgen plc - Interim results for the six months ended 30 June 2020
